No description available.

Traditionally, inoperable or metastatic cancers have been treated by causing massive DNA damage in order to induce self-destruction (apoptosis) of the rapidly multiplying cancer cells. Initially, this strategy works for many cancers, in particular those which express normal p53 tumor suppressor protein. However, most cancers eventually aquire mutations in either p53 or other signaling molecules and fail to initiate apoptosis in response to severe DNA damage. During this study three types of compounds were investigated for their DNA damaging and anticancer effects: a pair of novel metal containing compounds, a pair of natural products, and a known synthetic drug which had been used many years ago for completely different indication. It was shown that all stop the growth of cancer cells and that the latter two classes do not require functional p53 because they work equally well in cells with normal (wildtype), mutant or no p53. The two nickel complexes investigated in this dissertation, differ in their ability to cause DNA damage and cell death. The oxidized form of the nickel complex, [Ni(CR-2H)] 2+ causes DNA damage and cell death at a much lower concentration than its reduced counterpart [Ni(CR)] 2+ . The phenanthridine alkaloids, Sanguinarine and Chelerythine cause high levels of DNA strand breaks and extremely rapid apoptosis which is not due to DNA damage because the quick onset precludes extensive signaling. The effects of the phenanthridines were linked to production of large amounts of reactive oxygen species (ROS), in particular hydrogen peroxide (H 2 O 2 ). The importance of ROS for the action of anticancer drugs as well as antibiotics is increasingly being recognized. In addition we also investigated the thioxanthone Lucanthone or Miracil D (which was used for the treatment of parasitic worms more than 50 years ago). It causes DNA strand breaks and apoptosis. Apoptosis occurs on a timescale consistent with signaling. However, p53 does not seem to be involved and alternative mechanisms are being investigated. This work provides new directions for designing novel anticancer drugs that are not subject to the limitations of DNA damaging agents.

New chimeric inhibitors targeting the epidermal growth factor (EGFR) and histone deacetylases (HDACs) were synthesized and tested for antineoplastic efficiency in solid cancer (prostate and hepatocellular carcinoma) and leukemia/lymphoma cell models. The most promising compounds, 3BrQuin-SAHA and 3ClQuin-SAHA, showed strong inhibition of tumor cell growth at one-digit micromolar concentrations with IC50 values similar to or lower than those of clinically established reference compounds SAHA and gefitinib. Target-specific EGFR and HDAC inhibition was demonstrated in cell-free kinase assays andWestern blot analyses, while unspecific cytotoxic effects could not be observed in LDH release measurements. Proapoptotic formation of reactive oxygen species and caspase-3 activity induction in PCa and HCC cell lines DU145 and Hep-G2 seem to be further aspects of the modes of action. Antiangiogenic potency was recognized after applying the chimeric inhibitors on strongly vascularized chorioallantoic membranes of fertilized chicken eggs (CAM assay). The novel combination of two drug pharmacophores against the EGFR and HDACs in one single molecule was shown to have pronounced antineoplastic effects on tumor growth in both solid and leukemia/lymphoma cell models. The promising results merit further investigations to further decipher the underlying modes of action of the novel chimeric inhibitors and their suitability for new clinical approaches in tumor treatment.

As part of an International Cooperative Biodiversity Group (ICBG), extracts of plants from Suriname and Madagascar were bioassayed for cytotoxicity and antimalarial activity. Six cytotoxic extracts and one potential antimalarial were selected for fractionation, and yielded a number of bioactive compounds which were characterized by spectroscopy methods. Craspidospermum verticillatum (Apocynaceae) yielded four known indole alkoids. Casimirella sp (Icacinaceae) gave three new and five known diterpenoids. Pentopetia androsaemifolia (Apocynaceae) afforded one new and three known cardenolide glycosides. Physalis angulata (Solanaceae) yielded seven known physalins. Roupellina boivinnii (Apocynaceae) yielded four known and three new cardenolide glycosides, and three known cucurbitacins were isolated from Octolepis aff. dioica (Thymelaeaceae). In addition to these structural studies, a synthetic approach to lucilactaene, a cell cycle inhibitor was developed. / Ph. D.

<p dir="ltr"><b>Background</b></p><p dir="ltr">Recent developments in cancer therapeutics have allowed increased use of Oral Anticancer Medications (OAMs), including in the treatment of breast cancer. Breast cancer is the most common cancer among women in the United States. Patients with breast cancer may face key barriers in managing their OAMs at home. These challenges can lead to sub-optimal adherence and lower the overall quality of life. Designing interventions that enhance the patient experience with use of OAMs requires a deeper understanding of barriers faced by patients as they navigate their cancer care journey. The objective of this study was to identify the unmet medication management needs of patients with breast cancer who are receiving OAMs and co-design an early prototype intervention with patients to support medication management needs of patients with breast cancer.</p><p dir="ltr"><b>Methods</b></p><p dir="ltr">Two phases comprise this study. Phase 1 involved patient-journey mapping to characterize the longitudinal experience of OAMs use among patients diagnosed with breast cancer. In phase 2, we conducted participatory design (PD) workshops to develop a prototype tool to address OAM needs identified in phase 1. All participants were recruited from an outpatient breast cancer clinic in Indianapolis. Eligible participants were: 18 years of age or older, diagnosed with breast cancer, and currently receiving an OAM. All participants completed a brief sociodemographic and health information questionnaire. In phase 1, enrolled persons participated in a journey mapping exercise through semi-structured interviews. Interviews were conducted either in-person or remotely via Zoom, based on participant preference. For each interview, two researchers and the participant collaborated to create individual patient journey maps to generate a concise visual storyboard focused on medication use experiences related to OAMs. The journey maps helped capture treatment timelines, key markers of medication use, and specific barriers faced by patients. Individual journey maps were consolidated to generate personas representing groups of patients with related characteristics, treatment types, goals, and unmet needs. In phase 2, three rounds of PD workshops were conducted using the focus group format to develop an early prototype intervention. In round one (inspiration stage), participants defined the problem space and prioritized a list of challenges amenable to solutions; in round two (ideation stage), participants generated multiple possible solutions and design ideas; and in round three (convergence stage), two design concepts were selected and evaluated by participants.</p><p dir="ltr"><b>Results</b></p><p dir="ltr">In phase 1, 12 interviews (11 females and 1 male) were completed. The median age of participants was 65.5 years (range, 37-75). Participants were divided into two groups based on their prescribed medication types: (1) specialty medication (palbociclib or ribociclib; n=4 patients) and (2) traditional medication (tamoxifen, anastrozole, or exemestane; n=8 patients). We defined ‘Specialty’ medications as those that require specialty pharmacies and ‘traditional’ medications as those obtainable in local community pharmacies. To represent participants across these two broad categories of medications, two personas were created. Participants who had been prescribed specialty medication reported difficulty navigating the insurance process during medication fills, while participants who prescribed traditional medication did not. Notably, the word “prior authorization” was not used by participants to explain the issues they experienced. While all participants reported having side effects from their medications, sub-optimal adherence (n=2) was reported among the traditional medication group only. Other participants taking traditional medications either found their own ways to manage side effects or simply reported: “dealing with side effects as I don’t want cancer.” Participants expressed coping with side effects by enduring them. Participants had few strategies to manage their side effects, often stating that “they didn’t think of reaching out to the doctor,” when asked. Additionally, participants mentioned needing more financial and emotional support during their treatment journey. In phase 2, each PD session was conducted with 4-5 participants and 2 researchers (the design panel). Participants identified key challenges including difficulties navigating resources and information as well as managing medication side effects. The design panel prioritized two design concepts, which were subsequently developed into two prototypes: 1) a physical breast cancer handbook; and 2) an interactive treatment navigation app for use on tablet and smartphone devices. Our team plans to consolidate, further develop, and evaluate these prototypes in subsequent work as a follow up to this pilot study.</p><p dir="ltr"><b>Conclusion</b></p><p dir="ltr">This study provides insight into the patient experience with OAMs. The personas created can be applied in designing interventions tailored to breast cancer patients’ needs and goals, while the consolidated journey maps identify potential areas for improvement. Adequate patient education and enhanced tools and processes are necessary to manage medication side effects effectively, ultimately leading to improved medication outcomes and assisting patients in navigating their treatment. The two design concepts require further revision prior to implementation and pilot testing.</p>

Yes / Despite significant preclinical promise as anticancer agents, vascular-disrupting agents have yet to fulfil their clinical potential due to systemic toxicities. ICT2588 is a tumour-selective MT1-MMP-targeted prodrug of azademethylcolchicine, ICT2552. We investigate activation of ICT2588 and subsequent release of ICT2552 in tumour cells, and examine its ability to induce G2/M cell cycle arrest. We also explore synergism between ICT2588 and ATR inhibition, since colchicine, in addition to its vascular-disrupting properties, is known to induce G2/M arrest, DNA damage, and trigger apoptosis. Several ATR inhibitors are currently undergoing clinical evaluation. The cellular activation of ICT2588 was observed to correlate with MT1-MMP expression, with selective release of ICT2552 not compromised by cellular uptake and prodrug activation mechanisms. ICT2588 induced G2/M arrest, and triggered apoptosis in MT1-MMP-expressing cells, but not in cells lacking MT1-MMP expression, while ICT2552 itself induced G2/M arrest and triggered apoptosis in both cell lines. Interestingly, we uncovered that the intracellular release and accumulation dynamics of ICT2552 subsequent to prodrug activation provided synergism with an ATR inhibitor in a way not observed with direct administration of ICT2552. These findings have important potential implications for clinical combinations of ICT2588 and DNA repair inhibitors.

The present thesis deals with different aspects of the chemistry of oxovanadium(IV) complexes, their interaction with double stranded DNA, photo-induced DNA cleavage, photo-enhanced cytotoxicity in visible light and red light and localisation and cellular uptake to understand the mechanism of cell death. Chapter I presents a general introduction on potential of transition metal complexes as photochemotherapeutic agents. A brief introduction about Photodynamic Therapy (PDT) as a new alternative to chemotherapy for treating cancer has been made. Various modes of interaction of small molecules with duplex DNA are described. Recent reports on metal-based photocytotoxicity, photo-induced DNA cleavage activity and cellular localization are presented in detail. Objective of the present investigation is also dealt in this Chapter. Chapter II of the thesis deals with the synthesis, characterization, DNA binding and photo-induced DNA cleavage activity of ternary oxovanadium(IV) complexes of ONO-donor 2-(2-hydroxybenzylideneamino)phenol (salamp) and phenanthroline bases to explore the photo-induced DNA cleavage activity in UV-A light of 365 nm and photocytotoxicity in visible light. Chapter III deals with the photo-induced DNA cleavage and photocytotoxicity of ternary oxovanadium(IV) complexes containing ONN-donor N-2-pyridylmethylidine-2-hydroxyphenylamine (Hpyamp) Schiff bases and phenanthroline bases. The objective of this work is to investigate the photo-induced DNA cleavage activity in near-IR light. Photocytotoxicity and cell cycle arrest have been studied in HeLa cancer cells. Chapter IV deals serendipitous discovery of planar triazinuim cationic species by vanadyl-assisted novel ring cyclization reaction. The compounds are synthesised, characterized and their DNA binding and anaerobic photoinduced DNA cleavage activity are presented. The importance of the thiazole moiety in the triazinuim species in cellular uptake has been investigated. Photocytotoxicity, localization and cell death mechanism have been studied in HeLa and MCF-7 cells. Chapter V describes the synthesis, characterization, DNA binding, photo-induced DNA cleavage activity and photocytotoxicity of oxovanadium(IV) complexes containing 2-(1H-benzimidazol-2-yl)-N-(pyridin-2-ylmethylene)ethaneamine (Hpy-aebmz) and curcumin as photosensitizer. The effect of conjugating naphthalimide on Hpy-aebmz on photoinduced DNA cleavage and photocytotoxicity has been studied. Cellular uptake, localization and mechanism of cell death induced by complexes have been investigated. Chapter VI presents ternary oxovanadium(IV) complexes having, 2-((1H-benzimidazol-2-yl)methylimino-methyl)phenol (Hsal-ambmz) and phenanthroline bases. The complexes were synthesized, characterized and their DNA binding property studied. Photo-induced DNA cleavage activity and photocytotoxicity in red light has been discussed. Anthracene has been conjugated to a tridentate ligand to investigate cellular uptake, localization and cell death mechanism. Mitochondria targeting property of the complexes having dipeptide has been studied and compared with clinically used drug Photofrin®. The references have been compiled at the end of each chapter and indicated as superscript numbers in the text. The complexes presented in this thesis are represented by bold-faced numbers. Crystallographic data of the complexes, characterized structurally by single crystal X-ray crystallography, are given in CIF format in the enclosed CD (Appendix-I). Due acknowledgements have been made wherever the work described is based on the findings of other investigators. Any unintentional omission that might have happened due to oversight or mistake is regretted.

Dans le cadre d’un programme de recherche dédié à la découverte de petites molécules à visée anticancéreuse, nous avons envisagé de concevoir des composés originaux dérivés de quinones. Notre premier objectif a été d’élaborer des mimes non-peptidiques de la protéine Smac, susceptibles de participer à relancer le phénomène d’apoptose, dont la structure est rigidifiée par des contraintes conformationnelles. Par ailleurs, les kinases et les phosphatases, jouant des rôles complémentaires de phosphorylation / déphosphorylation dans le cadre du contrôle du cycle cellulaire notamment, apparaissent aussi comme des cibles intéressantes. Une étude attentive de leurs inhibiteurs connus nous a permis de mettre en avant des analogies structurales qui nous ont conduit à vouloir synthétiser des motifs fonctionnalisés de dérivés de naphtoquinones.L’introduction directe de chaînes latérales aliphatiques sur nos substrats, par création de liaisons de type C(sp2)–C(sp3), a été rendue possible grâce au développement d’une méthodologie de décarboxylation radicalaire. Dans les conditions réactionnelles mises au point, le couple Ag(I)/S2O82- est utilisé comme initiateur radicalaire et autorise la génération de radicaux alkyles par décarboxylation d’acides aminés. L’introduction directe de cycles aromatiques fonctionnalisés, via la création de liaisons de type C(sp2)–C(sp2), a été réalisée par l’intermédiaire de la génération de radicaux aryles issus de sels de diazonium stables ou d’anilines. Les procédés décrits dans ce manuscrit nous ont permis d’apporter certains éclaircissements sur la réactivité des substrats et sur les mécanismes réactionnels impliqués. / In our ongoing course dedicated to the discovery of small anticancer molecules, we designed novel quinone derivatives. Our first objective was to fashion non-peptidic Smac mimics, able to trigger apoptosis in tumor cells, displaying a structure rigidified by conformational restrictions. Otherwise, the kinases and the phosphatases, acting as phosphorylating / dephosphorylating agents mostly in the control of the cell cycle, were thought to be other relevant biological targets. An intent study of their known inhibitors allowed us to underline trends in their chemical structure and made us plan the synthesis of functionalized naphthoquinones.A dedicated approach involving radical decarboxylation of amino acids allowed the introduction of aliphatic side chains on our substrates though C(sp2)–C(sp3) bond formation. Ag(I)/S2O82- was used as alkyl radical initiator and the direct C-H alkylation of the quinonic positions could take place. C(sp2)–C(sp2) bonds were created through aryl radicals generation from stable diazonium salts or anilines which allowed the direct C-H arylation of quinones. The procedures described along this manuscript let us formulate several advances on the substrates reactivity and on the reaction mechanisms involved.

Les traitements existants des métastases hépatiques du cancer colorectal montrent une efficacité insuffisante. Le projet GR5FU visait à améliorer cette efficacité et consistait à délivrer le 5-fluorouracile (5FU) dans le foie via son encapsulation dans des globules rouges (GR). Dans ce contexte, la modélisation visait à prédire la quantité de 5FU à encapsuler dans les GR pour atteindre une efficacité équivalente à celle du 5FU standard. Dans cette thèse, nous avons construit et implémenté un modèle mathématique multi-échelle qui relie l’injection du 5FU à son efficacité sur la croissance tumorale en intégrant sa pharmacocinétique et son mécanisme d’action intracellulaire. Des simulations de population de ce modèle, s’appuyant sur des paramètres de la littérature, nous ont permis (i) de reproduire des résultats cliniques montrant le pouvoir prédictif de l’enzyme Thymidylate Synthase (TS) et (ii) d’identifier deux prédicteurs potentiels de la réponse au 5FU à l’échelle d’une population virtuelle, en complément du niveau de TS : la vitesse de croissance tumorale et le métabolisme intracellulaire des pyrimidines. Nous avons également analysé, à l’aide de modèles à effets mixtes, (i) la croissance in vivo de la tumeur intra-hépatique VX2 sans traitement, tenant lieu de modèle animal de métastase hépatique, et (ii) la distribution plasmatique et hépatique du 5FU chez l’animal. Cette modélisation statistique nous a permis d’identifier les modèles décrivant des données expérimentales, d’estimer les paramètres de ces modèles et leur variabilité, et de générer une meilleure connaissance de la croissance de la tumeur VX2 et de la pharmacocinétique animale du 5FU, en particulier hépatique. Dans cette thèse, nous avons illustré comment l’intégration du métabolisme d’un médicament et de son mécanisme d’action dans un modèle global et la simulation de ce modèle à l’échelle d’une population virtuelle, constituent une approche prometteuse pour optimiser le développement d’hypothèses thérapeutiques innovantes en collaboration avec des expérimentateurs. / Existing treatments for liver metastases of colorectal cancer show a lack of efficacy. In order to improve the prognosis of patients, the GR5FU project has been implemented. It consisted in delivering the drug 5-fluorouracil (5FU) in the liver via its encapsulation in red blood cells (RBC) to increase its efficacy / toxicity ratio. In this context, the modeling aimed at predicting the amount of 5FU to encapsulate in RBC to achieve an efficacy equivalent to standard 5FU. In this thesis, we have created and implemented a multiscale mathematical model that links the injection of 5FU to its efficacy on tumor growth by integrating its pharmacokinetics and mechanism of intracellular action. Population simulations of this model, using parameters from the literature, allowed us (i) to reproduce clinical results showing the predictive power of TS enzyme level and (ii) to identify two potential predictors of response to 5FU at the level of a population of virtual patients, in addition to TS level. We also analyzed, using mixed effects models, (i) the in vivo growth of intrahepatic VX2 tumor without treatment, serving as an animal model of liver metastasis, and (ii) the distribution of 5FU in the animal’s organism. This statistical modelization enabled us to identify the models describing experimental data, to estimate the parameters of these models and their variability, and generate a better knowledge of VX2 tumor growth and animal 5FU pharmacokinetics. In this thesis, we illustrated how the integration of drug metabolism and its mechanism of action in a global model and the simulation of this model at the scale of a virtual population, form a promising approach to optimize the development of innovative therapeutic hypotheses in collaboration with experimentalists.

L'extraction par CO2 supercritique démontre les avantages d'un procédé de chimie verte en comparant ce procédé à la méthode d'extraction par solvant organiques et en tenant compte du degré de toxicité et de pollution du solvant. L'extraction par solvants organiques met en évidence l'influence du solvant d'extraction alors que l'extraction par CO2-SC met en évidence l'influence de différents paramètres dont la pression, la température, le temps de contact entre la matrice végétale et le CO2-SC, le diamètre moyen des particules et l'ajout d'un co-solvant. L'analyse chromatographique a permis d'identifier et de quantifier les flavonolignanes (silychristine, silydianine, silybine, taxifoline) dans les extraits de graines obtenus par solvants organiques et par CO2-SC avec co-solvant. A 220 bar, les concentrations en silydianine (38,87 mg/g) et en silybine (45,91mg/g) sont les plus élevés et à 40°C les concentrations en silychristine (31,97mg/g), en silydianine (38,87 mg/g) et en silybine (45,91mg/g) sont les plus importantes. Les extraits huileux obtenus à 220 bar et à 40°C des graines de Silybum marianum sont riches en acides gras : acide linoléique (65,22%), acide oléique (27,01%), acide palmitique (12,12%). L'activité antioxydante a été évaluée par deux tests : test DPPH et test ABTS. Ces deux tests sont complémentaires et ont permis de conclure que l'extrait ayant un effet antioxydant le plus important est l'extrait obtenu par CO2-SC à 220 bar et à 40°C. L'activité biologique de cet extrait est mise en évidence par rapport à une lignée cellulaire cancéreuse du colon Caco-2. La silychristine, la silydianine et la silybine ainsi que l'extrait obtenu par CO2-SC avec co-solvant (éthanol) à 220 bar et à 40°C ont été testés vis à vis de cette lignée cancéreuse. Ces expérimentations in vitro reflètent une activité cytotoxique quantifiable et une mortalité cellulaire des Caco-2 des flavonolignanes allant jusqu'à 71% / The supercritical CO2 extraction demonstrates the benefits of green chemistry process comparing with the method of organic solvents extraction and depending to toxicity and pollution solvent degree. Organic solvents extraction shows the solvent extraction influence, so that the SC-CO2 extraction highlights different parameters including pressure, temperature, contact time between the plant matrix and CO2 SC, the average particle diameter and the addition of a cosolvent. Chromatographic analysis identified and quantified four flavonolignans (silychristin, silydianin, silybin, taxifolin) in seed extracts obtained by organic solvents and SC-CO2 with cosolvent. At 220 bar, silydianin (38.87 mg / g) and silybin (45.91 mg / g) have highest concentrations and at 40°C silychristin (31.97 mg / g), silydianin (38.87 mg / g) and silybin (45.91 mg / g) have the most important concentrations. The oily extracts obtained at 220 bar and 40°C of Silybum marianum seeds are rich in fatty acids: linoleic acid (65.22%), oleic acid (27.01%), palmitic acid (12.12%). The antioxidant activity measured by two tests: DPPH and ABTS test. These two tests are complementary and confirm that the extract with the higher antioxidant effect is the extract obtained by SC-CO2 at 220 bar and 40°C. The biological activity of this extract is demonstrated with respect to a colon cancer cell line Caco-2. Silychristin, silydianin and silybin and the extract obtained by CO2-SC with co-solvent (ethanol) at 220 bar and 40°C were tested with respect to this line cancer. These experiments in vitro cytotoxic activity reflect estimable and cell death of Caco-2 flavonolignans of up to 71%